Cargando…

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma

AIM: Assess patient-level utility of suggested pretreatment biomarkers of sunitinib in advanced renal cell carcinoma. PATIENTS & METHODS: Kaplan–Meier analysis of data from a randomized, Phase II study (n = 292) suggested baseline predictive value for circulating soluble Ang-2 and MMP-2 and HIF-...

Descripción completa

Detalles Bibliográficos
Autores principales:	English, Patricia A, Williams, J Andrew, Martini, Jean-François, Motzer, Robert J, Valota, Olga, Buller, Richard E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549778/ https://www.ncbi.nlm.nih.gov/pubmed/26674983 http://dx.doi.org/10.2217/fon.15.290

Ejemplares similares

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2014)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial
por: Motzer, Robert J., et al.
Publicado: (2022)

A brief symptom index for advanced renal cell carcinoma
por: Eton, David T, et al.
Publicado: (2006)

Clinical Trial Simulations From a Model‐Based Meta‐Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy
por: Zierhut, ML, et al.
Publicado: (2016)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Diagnostic efficacy of systemic immune-inflammation biomarkers in benign prostatic hyperplasia using receiver operating characteristic and artificial neural network
por: Ahmed, Rasha, et al.
Publicado: (2023)

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
por: Cella, David, et al.
Publicado: (2014)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

Receiver Operating Characteristic (ROC) to Determine Cut-Off Points of Biomarkers in Lung Cancer Patients
por: Weiss, Heidi L., et al.
Publicado: (2004)

Evaluation of an optimal receiver operating characteristic procedure
por: Jeffries, Neal, et al.
Publicado: (2009)

Analyzing receiver operating characteristic curves with SAS
por: Gönen, Mithat
Publicado: (2007)

Receiver operating characteristic analysis in medical imaging
por: International Commission on Radiation Units and Measurements. Bethesda
Publicado: (2008)

Receiver operating characteristic analysis: an ally in the pandemic
por: García, Jezreel Pantaleón, et al.
Publicado: (2021)

Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting
por: Patel, Anup, et al.
Publicado: (2020)

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
por: Tomita, Y., et al.
Publicado: (2022)

Statistics review 13: Receiver operating characteristic curves
por: Bewick, Viv, et al.
Publicado: (2004)

Choice of criterion used in the receiver operating characteristic analysis
por: Habibzadeh, Farrokh, et al.
Publicado: (2017)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

Lognormal Lorenz and normal receiver operating characteristic curves as mirror images
por: Irwin, R. John, et al.
Publicado: (2015)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Receiver Operating Characteristic (ROC) Curve: Practical Review for Radiologists
por: Park, Seong Ho, et al.
Publicado: (2004)

Neyman-Pearson classification algorithms and NP receiver operating characteristics
por: Tong, Xin, et al.
Publicado: (2018)

Drawing Guidelines for Receiver Operating Characteristic Curve in Preparation of Manuscripts
por: Kim, Jeehyoung, et al.
Publicado: (2020)

Receiver operating characteristic curve: overview and practical use for clinicians
por: Nahm, Francis Sahngun
Publicado: (2022)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Evaluating and comparing biomarkers with respect to the area under the receiver operating characteristics curve in two-phase case–control studies
por: Huang, Ying
Publicado: (2016)

Tournament leave-pair-out cross-validation for receiver operating characteristic analysis
por: Montoya Perez, Ileana, et al.
Publicado: (2018)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Receiver Operating Characteristic Curve and Odds Ratio Should Be Used with Caution
por: Hong, Wandong, et al.
Publicado: (2011)

Understanding diagnostic tests – Part 3: Receiver operating characteristic curves
por: Aggarwal, Rakesh, et al.
Publicado: (2018)

Assessment of diagnostic accuracy of biomarkers to assess lung consolidation in calves with induced bacterial pneumonia using receiver operating characteristic curves
por: Martin, Miriam, et al.
Publicado: (2021)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
por: Rini, Brian I., et al.
Publicado: (2014)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapy
por: Yeo, Seung-Gu, et al.
Publicado: (2013)

ROCS: Receiver Operating Characteristic Surface for Class-Skewed High-Throughput Data
por: Yu, Tianwei
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_m22vgnndr3sr475ggsa5gun6ik